compound semaglutide being discontinued Compounded GLP-1 - & Tirzepatide Compounded Semaglutide: Is it Safe?

The American Diabetes Association's Standards of Care recommend GLP-1 receptor agonists as second-line therapy for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or high cardiovascular risk, regardless of baseline HbA1c [1]

Our compounding pharmacies are required to exclusively use ingredients from FDA-licensed facilities and test sterile compounds for potency, sterility, and purity

Understanding formulation beyond color Color tells you about B12 content

By Route of Administration, Injectables Remain the Backbone Through 2035 Injectable formulations account for nearly 99% of obesity GLP-1 therapy use in 2025, reflecting their status as the established delivery route for both semaglutide and tirzepatide

36, 23462350 (2013b)

Inject with confidence knowing the anatomy is working in your favor